Navigation Links
Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Date:12/4/2007

pletion of enrollment of the trial triggers a milestone payment from JDRF under this agreement.

About SB-509

SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). Sangamo is currently evaluating this ZFP Therapeutic in a second ongoing Phase 2 clinical trial for the treatment of moderate to severe DN; plans to initiate a third Phase 2 trial to evaluate the effect of SB-509 on the mobilization of stem cells in subjects with DN; and has a preclinical program targeting spinal cord injury. Sangamo has also announced a new clinical program, the initiation of a Phase 2 clinical trial in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) in the first half of 2008.

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs.

A total of 102 subjects have been enrolled into the trial. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group is being treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group is receiving an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a distribution pattern that targets the skeletal muscle adjacent to the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Investigat
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)INDIANAPOLIS, Dec. 4 The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes
(Date:12/4/2009)Workers Ensure Emergency Deliveries are Transported ,, PHILADELPHIA, Dec. 4 Teamster members employed by the Philadelphia chapter of the American Red Cross are hard at work educating the public abo
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 1Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 4Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 5Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 6Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 7Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 8Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 1Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 2Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 3Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 1Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 2Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 3
...d Muscle Society International Congress, SOUTH PL...TC), a biopharmaceutical company focused on the di...l-molecule drugs targeting,post-transcriptional co...from a Phase 2 clinical trial of PTC124 in patient...nonsense mutation. The results, which include data...
... Trial Results of First Pro-Healing Stent Also ...ONG KONG, Oct. 18 OrbusNeich,s Genous(TM),Bio-eng...ions about,innovation in interventional cardiology...catheter Cardiovascular Therapeutics symposium, TC...on Convention Center in,Washington, D.C. The line...
Other Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007 2
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
Breaking Medicine News(10 mins):Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
...duces personality types used frequently in consume...e are motivated by one of two fundamental needs: t... that will help them achieve hopes and aspirations... exercise self-control when they choose goal-pursu...
...ervice to Retail Markets, MUNDELEIN, Ill., Jan. 2...day the retail launch of its headline-making,salad...e will consist of Z Trim Ranch, Z,Trim Honey Dijon...ht to transfer some of our success from Z,Trim pro...
...special needs child, Chelle Brewer,s, story of tri...spouse alpha moms worl...ewer,s soldier,husband is nearing the end of a hal...a heart. She volunteers for the,USO, Soldier,s Lis...
...s that seem to influence outcome , , WEDNE...ns that predict patient response to the two common...a) and venlafaxine (Effexor) have been identified ...protein called P-gp, which removes drugs and other...
...ap or press a surface is essential for everyday li...y or an iPhone. But researchers at the University...ivial action is the result of a complex neuro-moto...omedical engineer Francisco Valero-Cuevas is worki...
...ef, researchers say , , WEDNESDAY, Jan. 23... back pain, non-steroidal anti-inflammatory drugs ...e effective than acetaminophen. , That,s the concl...SAIDs are "slightly effective" for short-term symp...
Other Medicine News:Health News:Your personality type influences how much self-control you have 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 3Health News:'Military Spouse of the Year 2008' Announced 2Health News:Genetics May Determine Antidepressants' Effectiveness 2Health News:What gives us fingertip dexterity? 2Health News:What gives us fingertip dexterity? 3Health News:NSAIDs No Better for Low Back Pain 2
... allows the physician to intubate the canaliculi i...anesthetic drops., ,The SRS is made of medical...25mm, 30mm and 35mm (disposable sizers sold separa...d head to provide fixation. Each head consists of ...
...s a peptide highly dependent on growth hormone and...ansported in serum by several IGF-binding proteins...ts of IGF-I are a useful adjunct to assessment of ... IGF-I concentration is strong evidence against GH...
...ystem built around the many positive attributes ,...of Logic Driven Incubation (LDI). LDI technology ,...ance with the fastest possible incubation times. ,...iac biomarkers and HCG to be run in around 15 ,m...
ACS:180 C-Peptide Assay
Medicine Products: